Multiple Myeloma Archives - DelveInsight

Multiple Myeloma

recent-biotech-pharma-lifescience-industry-news-updates-for-adagio-lyndra-bms-anixa
Adagio Raises $336 M; Lyndra’s Schizo Trial; BMS Opdivo for Gastric Cancer; Anixa Ovarian C...

Adagio Raises $336 Million to Advance Covid-19 Antibody TreatmentAn antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings fr...


Pfizer’s Somatrogon; SCONE device; ATG-010; SanBio in Neurology
Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL...

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, SomatrogonPfizer and Opko had joined hands in 2014 to develop somatrogon, a pediatric growt...


Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse
Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse

The Multiple Myeloma Market is expected to grow during the study period 2017-30 due to a rich and robust pipeline, increasing incidence, and higher demand for novel therapies.A cancer of plas...


recent-pharma-news
Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks ...

Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclis...


pharma news
Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval

Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation. Duchenne Muscular Dystrophy is...


Pharma news
Notizia

Sanofi’s Isatuximab combo extends lives in multiple myelomaPhase III trials of Sanofi’s investigational anti-CD38 monoclonal antibody, isatuximab combination therapy were successful in loweri...


Multiple myeloma market
Multiple Myeloma Day

Multiple Myeloma DayMultiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information ...


multiple myeloma
The changing landscape of Multiple Myeloma therapies market

Multiple Myeloma, the second most common type of malignant cancer first being Non-Hodgkin lymphoma, is a type of cancer which is formed due to the presence of malignant plasma cells in bone marrow...


Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO.  A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but ...


AZ offloads; Pfizer’s deal; Takeda’s work on plant; Germany’s doc payment

AstraZeneca offloads headache drug Zomig to Grünenthal to raise $300M cash AstraZeneca had some positive news to announce at ASCO about its PARP Lynparza for treating breast cancer, but all in all,...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.